Benefits of a Continuous Ambulatory Peritoneal Dialysis (CAPD) Technique with One Icodextrin-Containing and Two Biocompatible Glucose-Containing Dialysates for Preservation of Residual Renal Function and Biocompatibility in Incident CAPD Patients

Hye Eun Yoon, Yoon Kyung Chang, Seok Joon Shin, Bum Soon Choi, Byung Soo Kim, Cheol Whee Park, Ho Cheol Song, Sun Ae Yoon, Dong Chan Jin, and Yong–Soo Kim

Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

Received: 28 February 2014
Accepted: 19 June 2014

Address for Correspondence:
Yong-Soo Kim, MD
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea
Tel: +82.2-2258-6036, Fax: +82.2-599-3589
E-mail: kimmc@catholic.ac.kr

In a prospective randomized controlled study, the efficacy and safety of a continuous ambulatory peritoneal dialysis (CAPD) technique has been evaluated using one icodextrin-containing and two glucose-containing dialysates a day. Eighty incident CAPD patients were randomized to two groups; GLU group continuously using four glucose-containing dialysates (n = 39) and ICO group using one icodextrin-containing and two glucose-containing dialysates (n = 41). Variables related to residual renal function (RRF), metabolic and fluid control, dialysis adequacy, and dialysate effluent cancer antigen 125 (CA125) and interleukin 6 (IL-6) levels were measured. The GLU group showed a significant decrease in mean renal urea and creatinine clearance (Δ-1.2 ± 2.9 mL/min/1.73 m², P = 0.027) and urine volume (Δ-363.6 ± 543.0 mL/day, P = 0.001) during 12 months, but the ICO group did not (Δ0.5 ± 2.7 mL/min/1.73 m², P = 0.266; -Δ108.6 ± 543.3 mL/day, P = 0.246). Peritoneal glucose absorption and dialysate caloric load were significantly lower in the ICO group than the GLU group. The dialysate CA125 and IL-6 levels were significantly higher in the ICO group than the GLU group. Dialysis adequacy, β2-microglobulin clearance and blood pressure did not differ between the two groups. The CAPD technique using one icodextrin-containing and two glucose-containing dialysates tends to better preserve RRF and is more biocompatible, with similar dialysis adequacy compared to that using four glucose-containing dialysates in incident CAPD patients. [Clinical Trial Registry, ISRCTN23727549]

Keywords: Biocompatibility; Peritoneal Dialysis, Continuous Ambulatory; Icodextrin, Randomized Controlled Trial; Residual Renal Function

INTRODUCTION

Preservation of residual renal function (RRF) has consistently been an independent predictor of mortality and cardiovascular death in peritoneal dialysis (PD) patients (1-8). Recently, the contribution of low glucose degradation product (GDP) solutions to the preservation of RRF has been evaluated. In the 3 out of 5 prospective randomized controlled studies comparing low GDP solution with conventional solution, the low GDP solution better preserved RRF (9-13). Among the randomized controlled trials using icodextrin in continuous ambulatory peritoneal dialysis (CAPD) patients (14-16), there are conflicting results regarding the effect of icodextrin on RRF. A previous study reported that icodextrin better preserved urine volume compared with 2.27% glucose solution during 6 months (14). Another recent study demonstrated that a combination of three biocompatible PD solutions including icodextrin better preserved urine volume during 12 months (15). On the other hand, a randomized controlled trial showed similar decline in urine volume and renal creatinine clearance (CrCl) between icodextrin and glucose solution for 2 yr in diabetic PD patients (16). Therefore, more randomized long-term studies are required in various patient populations to clarify the advantage of icodextrin over the glucose solution in terms of preserving RRF.

There is a broad consensus that a minimum of weekly Kt/Vtarget of 1.7 must be reached in PD (17, 18). However, it is not clear whether CAPD should begin with a full dose with four exchanges a day or begin with a smaller dose and increase the dose according to the parameters, such as solute clearance and ultrafiltration (UF), in incident CAPD patients having RRF. Although small dose CAPD by fewer exchanges a day is expected to give lower peritoneal solute clearance and UF compared with
full dose CAPD, adequate solute clearance and volume control can be achieved by RRF in incident CAPD patients. Furthermore, it may have advantages of lower burden of glucose, better quality of life, lower peritonitis rate and better preservation of RRF based on the clinical results of incremental PD (19, 20). We designed a prospective randomized controlled study to assess clinical benefits and safety of three daily exchanges CAPD technique using one icodextrin-containing and two neutral-pH, low GDP glucose-containing dialysates in incident CAPD patients. The primary outcome was change in RRF. Secondary outcomes were volume control, dialysis adequacy, and biocompatibility.

MATERIALS AND METHODS

Patients
Eighty end-stage renal disease patients starting CAPD from dialysis centers of 8 hospitals of the Catholic University of Korea, College of Medicine were enrolled from June 2007 to February 2009. Exclusion criteria included bedridden status, dependency on tube feeding, advanced liver cirrhosis, and current malignancy.

Study design
A multicenter, prospective, randomized, controlled trial was conducted. This study was registered with the International Standard Randomised Controlled Trial Number Registry (ISRCTN23727549). After enrollment, patients were randomly assigned to one of the two groups, and used four exchanges of glucose-containing dialysates (Physioneal, Baxter Healthcare, Woodlands, Singapore) a day. Randomized assignment was maintained by personnel not directly involved in the study. After one month (represents 0 month), patients in the control group (GLU) continuously used four exchanges of glucose-containing dialysates (Physioneal) a day. Patients in the treatment group (ICO) used one icodextrin solution (Extraneal, Baxter Healthcare, Woodlands, Singapore) for the long dwell (12-hr) and two exchanges of glucose-based dialysates (Physioneal) a day. Liberal use of 1.5%, 2.5%, or 4.25% glucose-based dialysates was allowed in both groups to achieve adequate control of edema and blood pressure. All patients were prescribed loop diuretics at baseline, and the dose of loop diuretics were not changed during the study. Visits were scheduled every month, and clinical evaluations were done in each visit. Peritoneal equilibration test was done at 0 month. Laboratory assessments were done at 0 month and every three months for hematological and serum chemistry data. Urine and peritoneal effluent samples were analyzed every six months for glucose, urea, creatinine and sodium levels and cancer antigen 125 (CA125) and interleukin-6 (IL-6) levels. Plain radiographs for chest were taken every six months. The study period was 12 months after randomization.

Sample size
The sample size was based on a power analysis to detect a 30% difference in proportion of patients with less than 50% reduction of RRF between two groups (α = 0.05, 1-β = 0.8). This resulted in a sample size of 39 patients in each group.

Clinical and biochemical assessments
Body weight, blood pressure (BP), prescription schedule and net peritoneal UF volume were assessed on 0 month and every three months. UF volume was averaged from peritoneal effluent volumes of three consecutive days before each visit. Dialysis adequacy, peritoneal creatinine clearance (peritoneal CrCl), mean of renal urea and creatinine clearance (renal CrCl), urine volume, β2-microglobulin clearance (β2-MGCl), ratio of overnight dialysate and serum β2-microglobulin (D/Pβ2-MG), peritoneal glucose absorption, dialysate calorie load, insulin requirements, daily dialysate sodium load, and cardiothoracic index (CTI) on chest radiographs were assessed on 0 month and every six months. D/Pβ2-MG was calculated from serum and overnight dialysate, which was a glucose-containing dialysate in the GLU group and icodextrin in the ICO group. β2-MG was estimated by solid-phase, two-site chemiluminescent immunoassay with Immulite 2000 (Siemens, Erlangen, Germany). Dietary protein intake was estimated from the protein equivalent of nitrogen appearance (PNA) following the equation: PNA = 15.1 + 0.1945 urea appearance (mM/24 hr) + protein losses (g/24 hr) (21). The daily (24-hr) dialysate sodium loss was calculated from the directly measured volume and sodium concentration of the daily drained dialysates minus the infused dialysate volumes and sodium concentrations during the 24-hr time interval. The daily (24-hr) peritoneal glucose absorption was calculated from the infused dialysate volumes and glucose concentrations during the 24-hr time interval minus the directly measured volume and glucose concentration of the daily drained dialysates. The dialysate calorie load was calculated from the sum of calorie from the dialysates used a day (22). In the 24-hr dialysate effluents, CA125 levels were measured by immunoradiometric assay using immunotech kit (Beckman Coulter, Prague, Czech Republic) and IL-6 levels were measured by sandwich ELISA (R&D Systems, Minneapolis, MN, USA) every six months. The intra- and inter-assay coefficients of variation were 2.0% and 3.8%, respectively. The dialysate sodium, glucose, CA125 and IL-6 levels and plasma sodium levels were measured in the central laboratory of Seoul St. Mary’s Hospital. Other biochemical data were measured in the laboratory of each participating hospital according to standard procedures. Events of peritonitis and cardiovascular disease were recorded in every visit. Cardiovascular events included coronary heart disease (angina pectoris or myocardial infarction), cerebrovascular disease (transient ischemic attack, cerebral infarction, or cerebral hemorrhage), peripheral/pulmonary vascular disease, and heart failure.
Statistical analysis
There was no patient who crossed over the two groups. At 6 months, there were 34 (GLU group) and 36 (ICO group) patients with data; at 12 months, these were 33 and 35 patients, respectively. In intention-to-treat analysis, mean values between groups were compared at 0, 6, and 12 months using unpaired Student’s t-test. A mixed-model longitudinal data analysis was used to test for an effect of treatment on the primary endpoints, change in renal CrCl and urine volume, with age and gender as covariates. As 12 patients (15.0%) dropped out during the study, we analyzed the change in parameters in each group using paired t-tests and by including only patients who fulfilled the study (per-protocol analysis; 33 patients in GLU group and 35 patients in ICO group). Also the change in serial measurements over time was analyzed by repeated measures analysis of variance (ANOVA). Proportions between groups were compared using chi-square tests or Fisher’s exact tests. A P value less than 0.05 was taken to indicate statistical significance. Values are presented as mean ± standard deviation.

Ethical statement
The study protocol complies with the Declaration of Helsinki and was approved by the institutional review board of the Catholic University of Korea, College of Medicine (KCMO08MI035). All patients provided informed consent before study entry.

RESULTS
Baseline characteristics
Eighty patients were enrolled and randomized. Sixty-eight patients completed the 12-month protocol (GLU group, n = 33; ICO group, n = 35; Fig. 1). Baseline characteristics are shown in Table 1. The mean ratio of dialysate to plasma creatinine (D/P creatinine at 4 hr) was significantly higher in the ICO group than the GLU group. However the proportions of peritoneal membrane transport types were not different between the 2 groups.

Residual Renal Function (RRF)
The renal CrCl and daily urine volume were measured for assessment of RRF. There was no statistical difference in renal CrCl (mL/min per 1.73 m²) at 0, 6, and 12 months between the two groups (GLU vs. ICO; 0-mo, 5.9 ± 1.6 vs. 5.7 ± 2.6, P = 0.758; 6-mo, 4.8 ± 2.6 vs. 5.3 ± 3.5, P = 0.477; 12-mo, 4.5 ± 2.9 vs. 5.1 ± 3.1, P = 0.426). When analyzed by the mixed model with adjustments for age and gender, there was no statistical difference in renal CrCl between the two groups (P = 0.783). In per-protocol analysis, the GLU group showed a significant decline in renal CrCl at 12 month from 0 month (P = 0.027), but the ICO group did not. Repeated measures ANOVA showed that there was no significant treatment effect on the change in renal CrCl (P = 0.528) (Fig. 2A).

Daily urine volume (mL per day) was significantly higher in the ICO group than the GLU group at 12 month (GLU vs. ICO; 0-mo, 1,024 ± 609 vs. 1,066 ± 522, P = 0.736; 6-mo, 760 ± 502 vs. 969 ± 542, P = 0.102; 12-mo, 649 ± 458 vs. 967 ± 553, P = 0.012). When analyzed by the mixed model with adjustments for age

| Parameter                     | GLU (n = 39) | ICO (n = 41) | P   |
|-------------------------------|-------------|-------------|-----|
| Male, No. (%)                 | 23 (69.0)   | 19 (46.3)   | 0.258 |
| Age (yr)                      | 54 ± 13     | 53 ± 12     | 0.892 |
| Cause of ESRD, No. (%)        |             |             | 0.570 |
| Diabetes                      | 23 (69.0)   | 20 (48.8)   |     |
| Hypertension                  | 8 (20.5)    | 11 (26.8)   |     |
| Glomerulonephritis            | 2 (5.1)     | 7 (17.1)    |     |
| Others                        | 6 (15.4)    | 3 (7.3)     |     |
| Body mass index (kg/m²)       | 22.7 ± 2.6  | 23.3 ± 3.9  | 0.373 |
| Hemoglobin (g/dL)             | 11.3 ± 1.7  | 11.3 ± 1.3  | 0.892 |
| Blood urea nitrogen (mg/dL)   | 57.9 ± 21.5 | 50.6 ± 19.7 | 0.120 |
| Serum creatinine (mg/dL)      | 7.1 ± 2.4   | 6.1 ± 1.9   | 0.058 |
| Serum albumin (g/dL)          | 3.6 ± 0.4   | 3.5 ± 0.5   | 0.238 |
| Total cholesterol (mg/dL)     | 182.9 ± 49.5| 190.6 ± 39.7| 0.442 |
| Triglyceride (mg/dL)          | 136.8 ± 69.1| 157.6 ± 65.2| 0.173 |
| LDL-C (mg/dL)                 | 113.3 ± 37.7| 119.0 ± 32.7| 0.476 |
| HDL-C (mg/dL)                 | 47.1 ± 16.4 | 45.3 ± 15.5 | 0.624 |
| Systolic BP (mmHg)            | 138.1 ± 17.9| 130.2 ± 17.8| 0.062 |
| Diastolic BP (mmHg)           | 81.0 ± 10.9 | 80.6 ± 10.1 | 0.886 |
| D/P creatinine at 4 hr        | 0.62 ± 0.17 | 0.70 ± 0.11 | 0.016 |
| Type of membrane transport (%)|            |             | 0.059 |
| Low                           | 15 (38.5)   | 6 (14.6)    |     |
| Low average                   | 10 (25.6)   | 14 (34.1)   |     |
| High average                  | 6 (15.4)    | 9 (22.0)    |     |
| High                          | 8 (20.5)    | 12 (29.3)   |     |
| Renal CrCl (mL/min/1.73 m²)   | 5.9 ± 1.6   | 5.7 ± 2.6   | 0.758 |
| Urine volume (mL/day)         | 1,023 ± 609 | 1,066 ± 522 | 0.736 |

Values are presented as mean ± SD. ESRD, end-stage renal disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure; D/P creatinine, ratio of dialysate to plasma creatinine; renal CrCl, mean of renal urea and creatinine clearance.

Fig. 1. Enrollment, randomization and follow-up of patients. HD, hemodialysis; APD, automated peritoneal dialysis.
and gender, there was no statistical difference in renal CrCl between the two groups ($P = 0.060$). In per-protocol analysis, the GLU group showed a significant decline in urine volume at 6 and 12 months from 0 month ($P = 0.022$ and $P = 0.001$, respectively), but the ICO group did not. Repeated measures ANOVA showed that there was no significant treatment effect on the change in urine volume ($P = 0.104$) (Fig. 2B).

**Markers for volume status**

Measurements of daily urine and peritoneal UF volume, dialysate sodium loss, body weight, CTI, and BP were used as surrogate markers for volume status (Table 2). The daily urine volume was significantly higher in the ICO group than the GLU group at 12 month, and it significantly decreased in the GLU group, but not in the ICO group. The GLU group showed a significantly higher peritoneal UF volume than the ICO group at 6 months, and the GLU group showed a significant increase in the peritoneal UF volume at 6 and 12 months ($P < 0.001$), but the ICO group did not. Therefore, the total output (sum of urine volume and net UF volume) was not different between the two groups.

### Table 2. Output volume, peritoneal sodium removal, body weight, cardiothoracic index and blood pressure

| Parameters                  | Timing   | GLU group               | ICO group               | $P$   | $P^1$ |
|-----------------------------|----------|-------------------------|-------------------------|-------|-------|
| Urine volume (mL/day)       | 0 month  | 1024 ± 609              | 1066 ± 522              | 0.736 | 0.104 |
|                            | 6 month  | 760 ± 502               | 909 ± 542               | 0.102 |       |
|                            | 12 month | 649 ± 458               | 967 ± 533               | 0.012 |       |
| Net UF volume (mL/day)      | 0 month  | 676 ± 459               | 820 ± 428               | 0.151 |       |
|                            | 6 month  | 1048 ± 447              | 844 ± 336               | 0.032 | 0.382 |
|                            | 12 month | 1034 ± 470              | 921 ± 332               | 0.264 |       |
| Total output (mL/day)       | 0 month  | 1699 ± 318              | 1886 ± 618              | 0.181 |       |
|                            | 6 month  | 1808 ± 490              | 1801 ± 595              | 0.958 | 0.479 |
|                            | 12 month | 1682 ± 239              | 1856 ± 664              | 0.246 |       |
| Dialysate sodium loss (mEq/day) | 0 month   | -107.8 ± 243.0          | -118.4 ± 227.3          | 0.753 |       |
|                            | 6 month  | -27.4 ± 213.5           | 21.8 ± 150.9           | 0.508 | 0.351 |
|                            | 12 month | -34.8 ± 243.5           | 38.2 ± 114.2           | 0.175 |       |
| Body weight (kg)            | 0 month  | 59.9 ± 9.0              | 60.5 ± 10.9             | 0.788 |       |
|                            | 6 month  | 61.3 ± 8.7              | 62.4 ± 11.7             | 0.640 | 0.699 |
|                            | 12 month | 62.7 ± 9.0              | 62.9 ± 11.6             | 0.919 |       |
| Cardi thoracic index (%)    | 0 month  | 48.8 ± 6.5              | 48.7 ± 7.6              | 0.915 |       |
|                            | 6 month  | 50.0 ± 7.2              | 48.0 ± 7.3              | 0.405 | 0.739 |
|                            | 12 month | 50.0 ± 7.2              | 49.0 ± 7.1              | 0.896 |       |
| Systolic BP (mmHg)          | 0 month  | 138.1 ± 17.9            | 130.2 ± 17.8            | 0.062 |       |
|                            | 6 month  | 134.3 ± 16.6            | 134.0 ± 19.9            | 0.938 | 0.195 |
|                            | 12 month | 134.1 ± 17.1            | 133.4 ± 21.5            | 0.886 |       |
| Diastolic BP (mmHg)         | 0 month  | 81.0 ± 10.9             | 80.6 ± 10.1             | 0.886 |       |
|                            | 6 month  | 80.5 ± 8.2              | 81.5 ± 12.1             | 0.694 | 0.990 |
|                            | 12 month | 79.6 ± 12.0             | 81.6 ± 12.5             | 0.513 |       |

Values are presented as mean ± SD. UF, ultrafiltration; BP, blood pressure. *$P$ values are analyzed by unpaired Student’s $t$-test; †$P < 0.05$ vs. 0 month analyzed by paired $t$-test; ‡$P$ values are analyzed by repeated measures ANOVA.
groups. There was no significant difference in the dialysate sodium loss between two groups during a year. However, the dialysate sodium loss significantly increased in the ICO group at 6 and 12 months ($P = 0.029$ and $P = 0.006$, respectively), but not in the GLU group. Body weight was not different between the two groups, but significantly increased during the study in both groups. CTI and absolute systolic and diastolic BP values were not different between the two groups and did not change significantly during the study in each group. Repeated measures ANOVA showed that there were no significant treatment effects on the changes in these volume-related parameters.

**Prescription of 2.5% glucose dialysates**

At 0 month, the proportion of patients using at least two 2.5% glucose dialysates per day was similar between the two groups (GLU, 21.2%; ICO, 20.0%). Over time, patients using at least two 2.5% glucose dialysates increased in the GLU group, but decreased in the ICO group, and the proportion was significantly higher in the GLU group than the ICO group (3-mo, 42.4% vs. 8.6%, $P = 0.002$; 6-mo, 42.4% vs. 11.4%, $P = 0.006$; 9-mo, 33.3% vs. 8.6%, $P = 0.016$; 12-mo, 51.5% vs. 14.3%, $P = 0.001$). Repeated measures ANOVA showed that there was a significant treatment effect on the change in dialysate calorie load at 12 month ($P = 0.002$), the ICO group showed a significant decrease at 6 and 12 months ($P < 0.001$). Repeated measures ANOVA showed that there was significant treatment effect on the change in peritoneal glucose absorption at 12 month ($P = 0.001$). The peritoneal β₂-MGCl was not different between the two groups, and the changes in peritoneal β₂-MGCl were not significant in each group. The D/Pβ₂-MGCl was significantly higher in the ICO group than the GLU group at 6 and 12 months ($P < 0.001$). The D/Pβ₂-MGCl did not change in the GLU group, but it significantly increased during the study in the ICO group. Repeated measures ANOVA showed that there was no significant treatment effects on the changes in these parameters.

**Dialysis adequacy and peritoneal β₂-microglobulin clearance**

The dialysis dose was adequate in both groups during the study (Table 3). The total KT/Vurea renal KT/Vurea and peritoneal KT/Vurea were not different between the two groups, and the changes from 0 month were not significant in each group. The protein intake of the patients, represented by nPNA, was also adequate. The peritoneal CrCl was not different between the two groups during the study. In per-protocol analysis, the peritoneal CrCl significantly increased in the GLU group at 6 month ($P = 0.03$), but not at 12 month. The ICO group did not show significant changes in peritoneal CrCl. Repeated measures ANOVA showed that there were no significant treatment effects on the changes in these parameters.

The peritoneal glucose absorption and dialysate calorie load

The peritoneal glucose absorption (g per day) was significantly lower in the ICO group than the GLU group at 6 and 12 months (GLU vs. ICO; 0-mo, 57.2 ± 30.8 vs. 53.3 ± 34.4, $P = 0.635$; 6-mo, 69.7 ± 18.6 vs. 30.2 ± 13.8, $P = 0.001$; 12-mo, 76.6 ± 23.1 vs. 31.5 ± 10.6, $P < 0.001$). While the GLU group showed a significant increase in daily peritoneal glucose absorption at 12 month ($P = 0.002$), the ICO group showed a significant decrease at 6 and 12 months ($P < 0.001$). Repeated measures ANOVA showed that there was significant treatment effect on the change in peritoneal glucose absorption ($P < 0.001$) (Fig. 3A).

The dialysate calorie load (Kcal per day) was significantly lower in the ICO group than the GLU group at 6 and 12 months (GLU vs. ICO; 0-mo, 423.9 ± 83.2 vs. 405.5 ± 69.9, $P = 0.326$; 6-mo, 450.3 ± 97.8 vs. 372.7 ± 44.6, $P < 0.001$; 12-mo, 478.9 ± 101.7 vs. 380.8 ± 63.3, $P < 0.001$). The GLU group showed a significant increase in the dialysate calorie load at 12 month ($P < 0.001$), but the ICO group showed a significant decrease at 6 month ($P = 0.023$) (Fig. 3B). Repeated measures ANOVA showed that there was significant treatment effect on the change in dialysate calorie load ($P < 0.001$). Insulin requirements (U per day) did not differ between the two groups (GLU vs. ICO; 0-mo, 41.3 ± 72.6 vs. 31.3 ± 26.5, $P = 0.459$; 6-mo, 41.1 ± 73.0 vs. 34.5 ± 36.3, $P = 0.344$; 12-mo, 55.6 ± 61.2 vs. 36.4 ± 36.2, $P = 0.367$), and the change in insulin doses was not significant in each group.

**Peritoneal effluent CA125 and IL-6 levels**

The dialysate CA125 levels (U per mL) were significantly higher in the GLU group than the ICO group at 6 and 12 months (GLU vs. ICO; 0-mo, 4.5 ± 1.0 vs. 4.3 ± 0.9, $P = 0.788$; 6-mo, 4.7 ± 1.6 vs. 4.2 ± 0.5, $P = 0.612$; 12-mo, 4.5 ± 1.3 vs. 4.1 ± 0.8, $P = 0.704$). The dialysate CA125 levels were not significantly different between the two groups, but the changes in the dialysate CA125 levels were significantly different between the two groups at 6 and 12 months ($P < 0.001$). The dialysate CA125 level in the ICO group significantly increased at 6 and 12 months ($P < 0.001$), in contrast to the GLU

### Table 3. Dialysis adequacy and β₂-microglobulin clearance

| Adequacy          | GLU group | ICO group | $P^*$ | $P^1$ |
|-------------------|-----------|-----------|-------|-------|
| Total KT/Vurea per week | 0 month   | 2.3 ± 0.8 | 2.7 ± 1.2 | 0.076 |
| 6 month           | 2.6 ± 1.3 | 2.5 ± 1.3 | 0.725 | 0.768 |
| 12 month          | 2.8 ± 1.7 | 2.7 ± 1.4 | 0.855 |       |
| Renal KT/Vurea per week | 0 month   | 1.3 ± 0.5 | 1.5 ± 0.8 | 0.060 |
| 6 month           | 1.3 ± 0.5 | 1.4 ± 1.1 | 0.584 | 0.442 |
| 12 month          | 1.4 ± 1.3 | 1.5 ± 1.1 | 0.770 |       |
| Peritoneal KT/Vurea per week | 0 month   | 1.0 ± 0.5 | 1.1 ± 0.5 | 0.201 |
| 6 month           | 1.3 ± 0.6 | 1.1 ± 0.4 | 0.061 | 0.474 |
| 12 month          | 1.3 ± 0.6 | 1.2 ± 0.5 | 0.253 |       |
| nPNA (g/kg/day)   | 0 month   | 1.2 ± 0.6 | 1.4 ± 0.5 | 0.213 |
| 6 month           | 1.3 ± 0.5 | 1.3 ± 0.5 | 0.875 | 0.714 |
| 12 month          | 1.2 ± 0.4 | 1.3 ± 0.5 | 0.458 |       |
| Peritoneal CrCl (ml/min/1.73 m²) | 0 month   | 4.4 ± 0.9 | 4.4 ± 0.9 | 0.788 |
| 6 month           | 4.4 ± 1.6 | 4.2 ± 0.5 | 0.612 | 0.704 |
| 12 month          | 4.5 ± 1.3 | 4.1 ± 0.8 | 0.447 |       |
| Peritoneal β₂-MGCl (ml/min/1.73 m²) | 0 month   | 0.6 ± 0.3 | 0.7 ± 0.4 | 0.174 |
| 6 month           | 0.7 ± 0.8 | 0.7 ± 0.2 | 0.949 | 0.210 |
| 12 month          | 0.6 ± 0.3 | 0.7 ± 0.2 | 0.076 |       |
| D/Pβ₂-MGCl        | 0 month   | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.980 |
| 6 month           | 0.1 ± 0.1 | 0.3 ± 0.1 | $< 0.001$ | $< 0.001$ |
| 12 month          | 0.1 ± 0.1 | 0.3 ± 0.1 | $< 0.001$ | $< 0.001$ |

Values are presented as mean ± SD. nPNA, normalized protein equivalent of nitrogen appearance; CrCl, creatinine clearance; β₂-MGCl, β₂-microglobulin clearance; D/Pβ₂-MGCl, ratio of overnight dialysate and serum β₂-microglobulin. *P values are analyzed by unpaired Student’s $t$-test; $P < 0.05$ vs. 0 month analyzed by paired $t$-test; $P$ values are analyzed by repeated measures ANOVA.
Fig. 3. Change in peritoneal glucose absorption and dialysate calorie load. (A) Peritoneal glucose absorption was significantly lower in the ICO group than the GLU group at 6 month and 12 month. While the peritoneal glucose absorption significantly increased in the GLU group (open circles) at 12 month, it significantly decreased in the ICO group (closed circles) at 6 month and 12 month compared with 0 month. (B) The dialysate calorie load was significantly lower in the ICO group than the GLU group at 6 month and 12 month. While the dialysate calorie load significantly increased in the GLU group (open circles) at 12 month, it significantly decreased in the ICO group (closed circles) at 6 month compared with 0 month. *P values were analyzed by unpaired Student’s t-test; †P values were analyzed by paired t-test; ‡P values were analyzed by repeated measures ANOVA.

Fig. 4. Change in peritoneal effluent CA125 and IL-6 levels. (A) The peritoneal effluent CA125 levels were significantly higher in the ICO group than the GLU group at 6 month and 12 month. In contrast to the GLU group (open circles), the ICO group (closed circles) showed a significant increase in effluent CA125 levels at 6 month and 12 month compared with 0 month. (B) The dialysate IL-6 level was significantly higher in the ICO group than the GLU group at 6 month and 12 month. While the effluent IL-6 levels did not change in the GLU group (open circles), it significantly increased in the ICO group (closed circles) at 6 month and 12 month compared with 0 month. Data are means±SEM. *P values were analyzed by unpaired Student’s t-test; †P values were analyzed by paired t-test; ‡P values were analyzed by repeated measures ANOVA.

group (Fig. 4A). Repeated measures ANOVA showed that there was significant treatment effect on the change in dialysate CA125 level (P < 0.001).

The dialysate IL-6 level (pg per mL) was significantly higher in the ICO group compared to the GLU group at 6 and 12 months (GLU vs. ICO; 0-mo, 12.3 ± 10.3 vs. 11.4 ± 8.1, P = 0.464; 6-mo, 11.1 ± 15.0 vs. 27.2 ± 20.2, P < 0.001; 12-mo, 12.0 ± 12.6 vs. 22.8 ± 12.4, P = 0.003). The dialysate IL-6 level in the ICO group also significantly increased at 6 and 12 months (P < 0.001 and P = 0.001, respectively), whereas the IL-6 level in the GLU group did not (Fig. 4B). Repeated measures ANOVA showed that there was significant treatment effect on the change in dialysate IL-6 level (P = 0.003).

Adverse events
The rate of peritonitis was 12.8% (n = 5) in the GLU group and 9.8% (n = 4) in the ICO group (P = 0.73). The rate of cardiovascular event was 2.6% (n = 1, cerebral infarction) in the GLU group and 2.4% (n = 1, angina pectoris) in the ICO group (P = 1.00). There was no significant difference in hemoglobin, albumin, calcium, phosphorus, aspartate aminotransferase and alanine aminotransferase levels between the two groups.

DISCUSSION
This is the first prospective, randomized, controlled study showing the benefits of a three daily exchanges CAPD technique using one icodextrin-containing and two low GDP, glucose-containing dialysates in incident CAPD patients. The present study demonstrated that the three daily exchanges CAPD technique using icodextrin was associated with better preservation of RRF and was more biocompatible in terms of glucose exposure and
preservation of mesothelial cell homeostasis, compared with the four exchanges CAPD technique using low GDP, glucose solutions in incident CAPD patients.

There are conflicting results regarding the effect of icodextrin on RRF in CAPD patients (14-16). In this study, urine volume was significantly higher in the ICO group than the GLU group at 12 month. The per-protocol analysis showed that the decline in renal CrCl and urine volume was significant in the GLU group, but not in the ICO group. These results suggest that the thrice-exchange technique using icodextrin may better preserve RRF. Although we have not identified the reason for preserving RRF by icodextrin, there are two possible explanations. First, icodextrin may reduce the extracellular fluid volume whilst protecting the patient from intravascular volume contraction. Previous reports showed increased plasma atrial natriuretic peptide levels, a marker of intravascular volume, when using icodextrin (23, 24). Low concentrations of high molecular weight icodextrin in plasma could potentially influence oncotic pressures and prevent intravascular volume depletion. Second, the UF rate may be slower during the thrice-exchange technique than the four times-exchange technique. The colloid oncotic pressure of icodextrin promotes UF at a lower rate than glucose (25), and the thrice-exchange requires less amounts of hypertonic dialysate. Therefore the less variation in the patients’ hemodynamic status may exert less ischemic damage to kidney. Third, less peritoneal UF volume may affect to better preserve RRF.

In terms of fluid removal, the GLU group showed significantly higher UF volume than the ICO group, which was associated with that the GLU group used more 2.5% glucose-containing dialysates. In every visit, the decision of glucose concentration of dialysate to prescribe was made according to the body weight, presence of edema, and BP. Therefore, it was likely that more use of 2.5% glucose-containing dialysates and consequent more UF volume in the GLU group attributed to the decreased urine volume, not vice versa. The ICO group maintained same volume status as the GLU group based on that there was no difference in total output, body weight, CTI and systolic and diastolic BP between the two groups. Maintaining the same volume status in the ICO group despite three daily exchanges was ascribed not only to the higher urine volume, but also to the superior net UF of icodextrin during long dwell compared with 2.5% or 4.25% glucose solutions (4, 14, 26-29). In terms of sodium removal, the dialysate sodium loss was not different between the two groups. However, the dialysate sodium loss significantly increased in the ICO group, but not in the GLU group. As icodextrin removes sodium more effectively than glucose solutions (14, 30), the amount of dialysate sodium removal was not lower in the ICO group than the GLU group despite of lower UF volume.

The continuous absorption of glucose during PD imposes a carbohydrate load that can lead to long term metabolic complications such as obesity and dyslipidemia (31, 32). In contrast to glucose, a slower absorption of carbohydrate from icodextrin results in a lower calorie load (33). In this study, both the glucose absorption and dialysate calorie load were significantly lower in the ICO group than the GLU group. These results clearly demonstrate the advantage of the thrice-exchange CAPD technique using icodextrin, in terms of less carbohydrate and calorie load.

Peritoneal effluent CA125 levels were measured as a marker of mesothelial cell mass and integrity (34). The effluent CA125 levels were significantly higher in the ICO group than the GLU group at 6 month and 12 month. This suggests that the peritoneal mesothelial cell layer was better preserved in the ICO group than the GLU group. GDs are known to cause damage to the peritoneal membrane (35). It can be explained that the lower glucose absorption of the ICO group resulted in better preservation of the mesothelial cell layer. IL-6 is a pleiotropic cytokine involved in inflammatory and immune responses (36). Whereas it was reported that IL-6 might reflect inflammation in the peritoneum (37), others suggested that the increase in IL-6 in biocompatible solutions may reflect increased preservation of mesothelial cells (15, 38). Our results are consistent with these studies, as the dialysate IL-6 levels were significantly increased in the ICO group compared with the GLU group. These results suggest that the increased mesothelial cell mass and preservation of the peritoneal membrane may have increased IL-6 levels in the ICO group.

Dialysis adequacy should be a concern with three daily exchanges CAPD technique because of low dialysis dose. As expected, the peritoneal CrCl was significantly lower in the ICO group than the GLU group at 6 month. However, the total Kt/V_ave levels were not different between the two groups and were within the acceptable range during a year. It was because that all patients were initially starting CAPD, who had enough RRF to compensate low dialysis dose. Although we cannot determine how long the patients can be maintained on a thrice-exchange CAPD, it is likely that this technique may be acceptable as long as if the dialysis adequacy is reasonable. Moreover, the peritoneal β2-MGCl was not different between the two groups. This may be because the peritoneal removal of β2-MG is higher in icodextrin than a glucose-containing dialysate (39). This study also showed that the D/P_β2-MG was significantly higher in the ICO group than the GLU group at 6 month and 12 month.

This study has some limitations. First the number of patients was small and the study period was not long enough to assess the long-term effect of the thrice-exchange CAPD technique using icodextrin on clinical outcomes. Second, whether a decrease in urine output or an increase in peritoneal UF became first is unclear. Third, a more accurate method for assessment of volume status was needed other than body weight, CTI and BP. Fourth, the mean D/P creatinine at 4 hr was different between the two groups. It is because stratification of D/P creatinine at 4 hr was not performed during randomization. The peri-
tunnel transport might have affected our results, and the thrice CAPD technique using one icodextrin-containing and two-glucose containing dialysates may be a better option for high peritoneal membrane transporters.

In conclusion, the CAPD technique using one icodextrin-containing and two glucose-containing dialysates a day shows a tendency of better preservation of RRF and is more biocompatible compared to the CAPD technique using four exchanges of low GDP glucose-containing dialysates, with comparable dialysis adequacy in incident CAPD patients.

**DISCLOSURE**

The authors have declared that no conflict of interest exists.

**ORCID**

Hye Eun Yoon http://orcid.org/0000-0002-6347-7282  
Yoon Kyung Chang http://orcid.org/0000-0003-4183-2034  
Seok Joon Shin http://orcid.org/0000-0001-7642-2849  
Bum Soon Choi http://orcid.org/0000-0002-1412-9551  
Byung Soo Kim http://orcid.org/0000-0001-5034-9014  
Cheol Whee Park http://orcid.org/0000-0002-9912-5393  
Ho Cheol Song http://orcid.org/0000-0002-9849-8091  
Sun Ae Yoon http://orcid.org/0000-0003-1175-8096  
Dong Chan Jin http://orcid.org/0000-0002-6637-8263  
Yong Soo Kim http://orcid.org/0000-0003-2152-1289

**REFERENCES**

1. Bargman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA Study. *J Am Soc Nephrol* 2001; 12: 2158-62.
2. Díaz-Buxo JA, Lowrie EG, Lew NL, Zhang SM, Zhu X, Lazarus JM. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. *Am J Kidney Dis* 1999; 33: 523-34.
3. Maiorca R, Brunori G, Zabani R, Cancarini GC, Manili L, Camerini C, Movilli E, Pola A, d’Avolio G, Gelatti U. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients: a longitudinal study. *Nephrol Dial Transplant* 1995; 10: 2295-303.
4. Panagiotou R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S; Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. *J Am Soc Nephrol* 2002; 13: 1307-20.
5. Rocco M, Soucie JM, Pastan S, McClellan WM. Peritoneal dialysis adequacy and risk of death. *Kidney Int* 2006; 58: 446-57.
6. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT; NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. *J Am Soc Nephrol* 2004; 15: 1061-70.
7. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, Sanderson JE. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. *J Am Soc Nephrol* 2004; 15: 2186-94.
8. Liao CT, Chen YM, Shiao CC, Hu FC, Huang JW, Kao TW, Chuang HF, Hung KY, Wu KD, Tsai TJ. Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. *Nephrol Dial Transplant* 2009; 24: 2609-14.
9. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. *Kidney Int* 2008; 73: 200-6.
10. Haag-Weber M, Krämer R, Haake R, Islam MS, Prischl F, Haug U, Nabut JL, Deppisch R; behalf of the DIUREST Study Group. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. *Nephrol Dial Transplant* 2010; 25: 2288-96.
11. Kim S, Oh J, Kim S, Chung W, Ahn C, Kim SG, Oh KH. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. *Nephrol Dial Transplant* 2009; 24: 2899-908.
12. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, Law MC, Li PK. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products: a 1-year randomized control trial. *Nephrol Dial Transplant* 2007; 22: 552-9.
13. Williams JD, Topley N, Craig KJ, Mackenzie R, Pischetsrieder M, Lage C, Passlick-Deetjen J; Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. *Kidney Int* 2004; 66: 408-18.
14. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimbürger O, Simonsen O, Davenport A, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. *J Am Soc Nephrol* 2003; 14: 2338-44.
15. Lui SL, Yung S, Yim A, Wong KM, Tong KL, Wong KS, Li CS, Au TC, Lo WK, Ho YW, et al. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. *Am J Kidney Dis* 2012; 60: 966-75.
16. Takatori Y, Akagi S, Sugiyama H, Inoue J, Kojo S, Morinaga H, Nakao K, Wada J, Makino H. Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial. *Clin J Am Soc Nephrol* 2011; 6: 1337-44.
17. Dombros N, Dramtwa M, Feriani M, Gokal R, Heimbürger O, Krediet R, Plum J, Rodrigues A, Selgas R, Strulvid D, et al. European best practice guidelines for peritoneal dialysis: 7 adequacy of peritoneal dialysis. *Nephrol Dial Transplant* 2005; 20: i24-7.
18. National Kidney Foundation. *KDQOI Clinical practice guidelines for peritoneal dialysis adequacy: guideline 2. peritoneal dialysis solute clear-

http://dx.doi.org/10.3346/jkms.2014.29.9.1217
ance targets and measurements. Am J Kidney Dis 2006; 49: S103-16.

19. De Vecchi AF, Scalamogna A, Finazzi A, Colucci P, Ponticelli C. Preliminary evaluation of incremental peritoneal dialysis in 25 patients. Perit Dial Int 2000; 20: 412-7.

20. Viglino G, Neri L, Barbieri S. Incremental peritoneal dialysis: effects on the choice of dialysis modality, residual renal function and adequacy. Kidney Int Suppl 2008; (108): S52-5.

21. Bergström J, Heimbürger O, Lindholm B. Calculation of the protein equivalent of total nitrogen appearance from urea appearance: which formulas should be used? Perit Dial Int 1998; 18: 467-73.

22. Gokal R, Mobery J, Lindholm B, Mujais S. Metabolic and laboratory effects of icodextrin. Kidney Int Suppl 2002; (81): S62-71.

23. Bouchi R, Babazono T, Inoue A, Tanaka M, Tanaka N, Hase M, Ishii A, Iwamoto Y. Icodextrin increases natriuretic peptides in diabetic patients undergoing CAPD. Perit Dial Int 2006; 26: 604-7.

24. Davies SJ, Garcia Lopez E, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimburger O, Simonsen O, et al. Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrol Dial Transplant 2008; 23: 2982-8.

25. Kendrick J, Teitelbaum I. Strategies for improving long-term survival in peritoneal dialysis patients. Clin J Am Soc Nephrol 2010; 5: 1123-31.

26. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16: 546-54.

27. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, Gerlag PG, Hournije SJ, Wolters J, van der Sande FM, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63: 1556-63.

28. Wolfson M, Piraino B, Hamburger RJ, Morton AR; Icodextrin Study Group. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40: 1055-65.

29. Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant 2000; 15: 862-6.

30. García-López E, Lindholm B, Davies S. An update on peritoneal dialysis solutions. Nat Rev Nephrol 2012; 8: 224-33.

31. Oda H, Keane WF. Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant 1998; 13: 45-9.

32. Bergström A, Nylander B, Moritz A, Jacobsson H, Rössner S. Increase of intra-abdominal fat in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1998; 18: 166-71.

33. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD: MIDAS Study Group: Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46: 496-503.

34. Visser CE, Brouwer-Steenberghen JJ, Betjes MG, Koemen GC, Beelen RH, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995; 10: 64-9.

35. Schwenger V, Morath C, Salava A, Amann K, Seregí N, Deppisch R, Ritz E, Bierhaus A, Nawroth PP, Zeier M. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17: 199-207.

36. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4: S233-42.

37. Martikainen T, Ekstrand A, Honkanen E, Teppo AM, Grönhagen-Riska C. Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? a 1-year follow-up study. Scand J Urol Nephrol 2005; 39: 410-6.

38. Witowski J, Topley N, Jörres A, Liberek T, Coles GA, Williams JD. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995; 47: 292-93.

39. Bruschi M, Candiano G, Santucci L, Petretto A, Mangraviti S, Canepa A, Perri K, Ghiggeri GM, Verrina E. Proteome profile of peritoneal effluents in children on glucose- or icodextrin-based peritoneal dialysis. Nephrol Dial Transplant 2011; 26: 308-16.